NCT04661930 - Fenofibrate for Patients With COVID-19 Requiring Hospitalization | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

May 1, 2022

Study Completion Date

July 1, 2022

Conditions

Corona Virus Disease (COVID-19)Respiratory Distress SyndromeSARS-CoV-2 Infection

Interventions

DRUG

TriCor® 145mg tablets

Fenofibrate; 145 mg daily (1/day); oral administration; 10 days

OTHER

Placebo

Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

OTHER

Usual care

All participants will otherwise receive usual medical care

Trial Locations (3)

RECRUITING

Barzilai Medical Center, Ashkelon

RECRUITING

Rambam Health Care Campus, Haifa

RECRUITING

Nazareth Hospital EMMS, Nazareth